Skip to main content
Log in

Repeated therapy in subgroups of female patients with IBS: who will respond and to which treatment?

  • Practice Point
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Thompson WG et al. (1999) Functional bowel disorders and functional abdominal pain. Gut 45 (Suppl 2): II43–II47

    PubMed  PubMed Central  Google Scholar 

  2. Drossman DA et al. (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123: 2108–2131

    Article  PubMed  Google Scholar 

  3. Lesbros-Pantoflickova D et al. (2004) Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20: 1253–1269

    Article  CAS  PubMed  Google Scholar 

  4. Coffin B et al. (2004) Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 53: 1465–1470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sabate JM et al. (2005) Antinociceptive effect of tegaserod in female IBS constipated patients [abstract]. Gastroenterology 128: A468

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Benoit Coffin.

Ethics declarations

Competing interests

Dr Coffin received an unrestricted grant from Novartis International to realize the study cited in reference 5. Dr Coffin had been a Consultant for Solvay Pharma France, Laboratoires Cephalon France and Novartis France.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coffin, B. Repeated therapy in subgroups of female patients with IBS: who will respond and to which treatment?. Nat Rev Gastroenterol Hepatol 3, 310–311 (2006). https://doi.org/10.1038/ncpgasthep0500

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0500

  • Springer Nature Limited

Navigation